Bernstein kept its 'Outperform' rating and expressed confidence in GSK's HIV division, supporting a favorable view. It also trimmed its target by 6 pence, but the small cut does not erase its confidence in long-term performance.
Confidence in steady HIV performance supports GSK's prospects over time. The target fell by 6 pence, but the analyst kept the 'Outperform' rating and said HIV's potential is underestimated.
Follow GlaxoSmithKline plc (GSK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GSK